News Briefs

businessman-viewing-news-update-journalism-headline-on-a-laptop
October 14

✦ Over the past five years, biosimilars created competition that resulted in savings of $9.8 billion. That’s according to Amgen Inc.’s 2021 Biosimilar Trends Report, its eighth edition. The therapies also have the potential to save people out-of-pocket costs of $238 million in the nine classes in which the agents have been approved. The drugs are launching with wholesale acquisition costs that are generally between 15% and 37% less than those of their reference products.

0
0 Comments
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-holding-a-cellphone
January 12

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
January 12

New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati

READ MORE
tubes
January 12

FDA Approved Four New Gene Therapies, Other Novel Agents in 2022

READ MORE
panalgo-building-an-effective-analytics-team

The Latest

Premium Categories

directory-of-health-plans-test-drive-directory-of-health-plans-ad

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today